

**S3 Table.** EORTC scores at the end of treatment

Dimension	CCRT with TMZ +TMZ 6 cycles (n=29)	RT only (n=26)	p-value <sup>a)</sup>
<b>EORTC QLQ-C30</b>			
<b>Global health status/QoL</b>			
Global health status/QoL	50.0 (8.3-91.7)	66.7 (16.7-100.0)	0.470
<b>Functional scales</b>			
Physical functioning	86.7 (20.0-100.0)	80.0 (26.7-100.0)	0.688
Role functioning	83.3 (0.0-100.0)	100.0 (16.7-100.0)	0.678
Emotional functioning	75.0 (25.0-100.0)	75.0 (41.7-100.0)	0.520
Cognitive functioning	83.3 (16.7-100.0)	100.0 (50.0-100.0)	0.582
Social functioning	66.7 (0.0-100.0)	66.7 (0.0-100.0)	0.839
<b>Symptom scales</b>			
Fatigue	22.2 (0.0-88.9)	22.2 (0.0-66.7)	0.476
Nausea and vomiting	0.0 (0.0-66.7)	0.0 (0.0-33.3)	0.333
Pain	0.0 (0.0-83.3)	16.7 (0.0-50.0)	0.670
Dyspnea	0.0 (0.0-66.7)	0.0 (0.0-33.3)	0.656
Insomnia	0.0 (0.0-66.7)	0.0 (0.0-66.7)	0.539
Appetite loss	0.0 (0.0-100.0)	0.0 (0.0-100.0)	0.458
Constipation	0.0 (0.0-100.0)	0.0 (0.0-100.0)	0.724
Diarrhea	0.0 (0.0-33.3)	0.0 (0.0-66.7)	0.763
Financial difficulties	0.0 (0.0-100.0)	33.3 (0.0-100.0)	0.218
<b>EORTC QLQ-BN20</b>			
Future uncertainty	25.0 (0.0-91.7)	25.0 (0.0-91.7)	0.539
Visual disorder	0.0 (0.0-100.0)	11.1 (0.0-66.7)	0.642
Motor dysfunction	11.1 (0.0-100.0)	0.0 (0.0-66.7)	0.061
Communication deficit	0.0 (0.0-88.9)	0.0 (0.0-88.9)	0.329
Headaches	33.3 (0.0-100.0)	33.3 (0.0-66.7)	0.662
Seizures	0.0 (0.0-66.7)	0.0 (0.0-33.3)	0.379
Drowsiness	33.3 (0.0-100.0)	33.3 (0.0-100.0)	0.244
Itchy skin	0.0 (0.0-66.7)	0.0 (0.0-33.3)	0.944
Hair loss	0.0 (0.0-66.7)	0.0 (0.0-66.7)	0.612
Weakness of legs	0.0 (0.0-100.0)	0.0 (0.0-66.7)	0.553
Bladder control	0.0 (0.0-66.7)	0.0 (0.0-33.3)	0.296

Values are presented as median (min-max). CCRT, concurrent chemoradiotherapy; EORTC, European Organization for Research and Treatment of Cancer; QLQ-BN20, 20-item EORTC QLQ-Brain Neoplasm; QLQ-C30, Quality of Life Questionnaire 30; QoL, quality of life; RT, radiotherapy; TMZ, temozolomide. <sup>a)</sup>Wilcoxon rank sum test.